Novavax Stock Fair Value Calculation – Novavax Stock Falls Thursday, Still Outperforms Market Despite 0.62% Drop

☀️Trending News

Novavax ($NASDAQ:NVAX) Inc.’s stock dropped 0.62% Thursday, closing the trading session at $8.06. Despite the fall, Novavax Inc. still managed to outperform the market, making it one of the few stocks to show positive gains. Novavax Inc. is a biopharmaceutical company that specializes in the research and development of vaccines and biotherapeutics.

Novavax has developed a range of vaccines for a variety of illnesses, such as the flu, HPV, and other infectious diseases. It is currently working on vaccines to address respiratory syncytial virus, seasonal influenza, and coronavirus.

Analysis – Novavax Stock Fair Value Calculation

GoodWhale has conducted thorough research on the fundamentals of NOVAVAX. After analyzing its financials, we have arrived at the intrinsic value of NOVAVAX share to be around $123.7, calculated using our proprietary Valuation Line. At present, the NOVAVAX stock is trading at just $8.2, which is 93.4% below its intrinsic value. This indicates that the company’s share is severely undervalued in the market and investors can take advantage of the current price dip. More…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Novavax. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Novavax. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Novavax. More…

Key Ratios Snapshot

Some of the financial key ratios for Novavax are shown below. More…

Peers

The competition between Novavax Inc and its competitors is fierce. Moderna Inc, BioNTech SE, and Pfizer Inc are all major players in the vaccine industry, and each company is striving to develop the most effective vaccine possible. While Novavax Inc has made great strides in recent years, its competitors are not far behind.

– Moderna Inc ($NASDAQ:MRNA)

Moderna Inc is a clinical stage biotechnology company that discovers, develops, and commercializes therapeutics and vaccines based on RNA. As of 2022, Moderna Inc has a market cap of 48.32B and a ROE of 80.28%. Moderna Inc’s mission is to harness the power of RNA to revolutionize medicine and change the way diseases are prevented, treated, and cured.

– BioNTech SE ($NASDAQ:BNTX)

As of 2022, BioNTech SE has a market cap of 32.44B and a Return on Equity of 71.82%. The company is a German biotechnology company that develops and manufactures vaccines and antibody therapeutics. The company has developed a platform that allows it to rapidly design and produce custom-made vaccines and therapeutics.

– Pfizer Inc ($NYSE:PFE)

Pfizer Inc is a pharmaceutical company with a market cap of 247.45B as of 2022. The company has a return on equity of 24.63%. Pfizer Inc is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets safe, effective, and affordable human and veterinary medicines. The company is one of the world’s largest research-based pharmaceutical companies, with products available in more than 150 countries.

Summary

Novavax Inc. is a prime example of a stock that has outperformed the market despite volatile trading, as evidenced by the 0.62% decline in its stock price on Thursday. Investing in Novavax Inc. is likely to remain a positive decision, given its potential to grow and become a leader in the vaccine industry.